Statins have several pleiotropic effects, beyond cholesterol synthesis inhibition, including antiinflammatory and antithrombotic properties. 1 They have been shown to reduce the rate of venous thromboembolism (VTE), but whether this beneficial effect is counterbalanced by an increased hemorrhagic risk is still debated. Herein, we report the results of a multicenter retrospective cohort study of patients taking vitamin K antagonists (VKA) for VTE. Our results suggest that statins do not increase the risk of bleeding during long-term VKA treatment.
Statin therapy may affect several steps of the blood coagulation cascade, including down-regulation of tissue factor expression, increased protein C activity and factor Va inactivation, and enhanced thrombomodulin expression. 2 The result consists in reduced thrombin generation and, therefore, decreased fibrinogen cleavage and platelet activation. 2 In a recent meta-analysis, the use of statins for primary or secondary cardiovascular prevention has been shown to reduce the risk of VTE by approximately 20%. 3 Furthermore, there is evidence that high-potency statins might give a greater protection against recurrent VTE than low-potency statins. [4] [5] On the other hand, high-dose atorvastatin was associated with increased rates of hemorrhagic stroke in a large randomized controlled trial of patients with previous stroke or transient ischemic attack (TIA). 6 However, these findings were not confirmed in a meta-analysis assessing the efficacy and safety of statins in patients with acute ischemic stroke or TIA. 7 Thus, the aim of this study was to evaluate the influence of statins on the risk of bleeding in VTE patients taking VKA.
This study is part of a project extensively described in a previous publication. 8 The total follow-up on VKA treatment was 500.59 patient-years (pt-y) and the median VKA treatment duration was 11.1 (IQR 6-12) months. The high prevalence of unprovoked VTE and VTE secondary to permanent risk factors (such as cancer) in our cohort can explain the need for longterm secondary prevention of VTE. The composite outcome of MB and CRNMB occurred in 50 patients, 11 statin-users and 39 non-users, corresponding to bleeding incidence rates of 10.7
(95%CI, 5.9-19.3) per 100 pt-y and 9.8 (95%CI, 7.2-13.4) per 100 pt-y, respectively. The number of MB and CRNMB separately and the respective incidence rates are reported in Table 2 . Twentythree of these events (8 in statin-users and 15 in non-users) occurred with INR in therapeutic range.
The Kaplan-Meier curves for the composite outcome were not significantly different in statin-users versus non-users (log rank test (Table 2) .
In multivariable analysis, adjusted for potential confounders and stratified by Centre, statin use did not correlate with the risk of any bleeding, MB or CRNMB only ( 14 Our study has potential limitations that need to be acknowledged. First, the observational design lacks the advantage of random treatment allocation. Although it is expected that statin-users have more cardiovascular risk factors than non-users (confounding by indication), we could not exclude the presence of the "healthy-user effect". Among patients with vascular history or dyslipidemia, who indeed might benefit from statins, this treatment is usually prescribed only to those with a better life expectancy, thus the nomenclature of "healthy-users". However, in our cohort of VTE patients, bleeding risk factors appeared to be well-distributed between the two groups: age and VTE provoking factors were not significantly different; statin-users had a greater prevalence of concurrent antiplatelet therapy, but also better anticoagulation control. Second, the use of statin was assessed at baseline, while information on the starting date and effective treatment duration was not available. Therefore, we could not perform a time-varying regression analysis. Third, cholesterol levels were available only in a minority of patients. Despite the retrospective data collection, patients included in our cohort were routinely followed by the Anticoagulation clinics, providing detailed follow-ups. However, differently from full blood count or renal function, lipid profile is usually not required during anticoagulant treatment. Finally, our follow-up time was not sufficiently long to evaluate the impact of statin use on the risk of recurrent VTE, which has a very low rate during VKA treatment.
The main strength of our study was the specific focus on overall clinically relevant bleeding complications during long-term VKA treatment for VTE secondary prevention in real-life clinical practice. All bleeding events were centrally reviewed and rigorously classified as MB or CRNMB.
In addition, the three most commonly used statins (atorvastatin, rosuvastatin and simvastatin), although administered at moderate doses, were well-represented in our cohort, allowing to generalize our findings to a statin class effect.
In conclusion, the concomitant use of statin and vitamin K antagonist appeared to be safe. This finding needs to be confirmed in larger prospective cohort studies.
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